Serglycin’s role in primary liver cancer: insights into tumor microenvironment and macrophage interaction
Open accessThe DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.
Abstract
Background: Serglycin (SRGN) is an important proteoglycan that regulates tumorigenesis, but its role in primary liver cancer (PLC) remains unclear. Methods: We investigated the expression and prognostic potential of SRGN in PLC using bioinformatics analyses. HepG2 cells were transfected with an SRGN over expression vector and their proliferation, migration, invasion, resistance to sorafenib, and angiogenic capacity were examined in vitro . A subcutaneous xenograft tumor model was created using nude mice. SRGN overexpressing hepatoma cells were co-cultured with THP-1 derived macrophages. The expressions of CD80 and CD206, secretory molecules, and the NF-κB and STAT3 signal pathways were examined by flow cytometry, ELISA and western blot, respectively. Transwell migration and invasion were investigated in HepG2 and Huh7 co-cultured with SRGN-promoted macrophages. Results: Single-cell analysis revealed SRGN expression across 17 distinct cell subpopulations, with higher expression in macrophages in tumor tissues compared to those in normal tissues. SRGN displayed consistent high expression across cell cycle phases while exhibited dynamic expression during macrophage pseudotime trajectory. Cell communication analysis indicated that SRGN was involved in interactions within the tumor microenvironment (TME), particularly in the VEGF signaling network. Autocrine SRGN promoted in vitro aggressiveness, especially pro-angiogenic activity, and in vivo tumorigenicity of HepG2 cells, and conferred resistance to sorafenib. Paracrine SRGN promoted a partial polarization of TAMs toward an M2-like phenotype, accompanied by the activation of signaling pathways including NF-κB and STAT3. Levels of secreted argase1 and SRGN were increased in the supernatant. The invasion and migration of hepatoma cells were promoted by SRGN-overexpressing TAMs. Conclusions: Our findings highlight the role of SRGN in the TME of PLC. SRGN-high TAMs are induced by paracrine SRGN from hepatoma cells, establishing a self-reinforcing mechanism that drives PLC progression. Therapeutic strategies targeting SRGN should take into account its context-specific roles depending on TME cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Cohen, J. (2013) · doi:10.4324/9780203771587 · Cited by 25,373
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440 · cited 1×
“Immune microenvironment characterization was performed using single-sample gene set enrichment analysis (ssGSEA) implemented via the GSVA package (34), utilizing 24 gene sets corresponding to immune cell signatures (35).”
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx247 · Cited by 9,849
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J. S., Li, B., & Liu, X. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0307 · Cited by 5,913
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,694 · cited 2×
“TIMER analysis suggested that SRGN expression was closely related to TME cells (Supplementary Tables 2, 3), which should be considered in multivariate Cox regression models.”
Pancancer survival analysis of cancer hallmark genes
Nagy, Á., Munkácsy, G., & Győrffy, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-84787-5 · Cited by 1,381
The human protein atlas: a spatial map of the human proteome
Thul, P. J., & Lindskog, C. (2018) · Protein Science · doi:10.1002/pro.3307 · Cited by 1,299
The CPTAC Data Portal: A Resource for Cancer Proteomics Research
Edwards, N. J., Oberti, M., Thangudu, R. R., Cai, S., McGarvey, P. B., Jacob, S., Madhavan, S., & Ketchum, K. A. (2015) · Journal of Proteome Research · doi:10.1021/pr501254j · Cited by 558
Menyhárt, O., Nagy, Á., & Győrffy, B. (2018) · Royal Society Open Science · doi:10.1098/rsos.181006 · Cited by 507
Tumor‐associated macrophages in liver cancer: From mechanisms to therapy
Cheng, K., Cai, N., Zhu, J., Yang, X., Liang, H., & Zhang, W. (2022) · Cancer Communications · doi:10.1002/cac2.12345 · Cited by 460 · cited 1×
“In addition, macrophages may be recruited through SRGN, as shown in myeloma (70) and disc degeneration (71).”
Immunosurveillance of the Liver by Intravascular Effector CD8 + T Cells
Guidotti, L. G., Inverso, D., Sironi, L., Di Lucia, P., Fioravanti, J., Ganzer, L., Fiocchi, A., Vacca, M., Aiolfi, R., Sammicheli, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.005 · Cited by 323 · cited 1×
“…described above, SRGN levels were highest in M2 macrophages than other three monocyte/macrophage subsets in liver tissues, LIHC, and adjacent normal by GEPIA, re fl ecting the liver ’ s natural immune tolerance, immunosuppressive properties and pro-tumorigenic characteristics, respectively (66, 67).”
Fang, W., Zhou, T., Shi, H., Yao, M., Zhang, D., Qian, H., Zeng, Q., Wang, Y., Jin, F., Chai, C., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01786-6 · Cited by 256
Li, B., & KWOK, H. F. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-108 · Cited by 205
Mause, S. F., Ritzel, E., Liehn, E. A., Hristov, M., Bidzhekov, K., Müller-Newen, G., Soehnlein, O., & Weber, C. (2010) · Circulation · doi:10.1161/circulationaha.109.909473 · Cited by 201 · cited 1×
“The JAK/ STAT pathway is associated with in fl ammation, invasion, the formation of new blood vessels, metastasis, and the initiation and progression of cancer (55), while the PI3K-AKT signaling pathway is a key regulator of cell proliferation and survival (56).”
M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling
Zong, Z., Zou, J., Mao, R., Ma, C., Li, N., Wang, J., Wang, X., Zhou, H., Zhang, L., & Shi, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01643 · Cited by 196 · cited 1×
“It has reported that PD-L1 is induced in M1 macrophages through IL-1beta signaling (68).”
Self-citationGiavazzi, R., Sennino, B., Coltrini, D., Garofalo, A., Dossi, R., Ronca, R., Tosatti, M. P. M., & Presta, M. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64325-8 · Cited by 185
Serglycin: A Structural and Functional Chameleon with Wide Impact on Immune Cells
Kolset, S. O., & Pejler, G. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100806 · Cited by 172
Serglycin: At the Crossroad of Inflammation and Malignancy
Korpetinou, A., Skandalis, S. S., Labropoulou, V. T., Smirlaki, G., Noulas, A., Karamanos, N. K., & Theocharis, A. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2013.00327 · Cited by 146
Role of the nervous system in cancer metastasis
Kuol, N., Stojanovska, L., Apostolopoulos, V., & Nurgali, K. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0674-x · Cited by 141 · cited 1×
“Since VEGF is a well-established driver of tumor angiogenesis and metastasis (61), and TAMs are recognized as key sources of pro-angiogenic factors including VEGF (62, 63), we hypothesized that SRGN may facilitate angiogenesis by augmenting VEGF signaling in the TME.”
Navakanitworakul, R., Hung, W.-T., Gunewardena, S., Davis, J. S., Chotigeat, W., & Christenson, L. K. (2016) · Scientific Reports · doi:10.1038/srep25486 · Cited by 140 · cited 16×
“Since VEGF is a well-established driver of tumor angiogenesis and metastasis (61), and TAMs are recognized as key sources of pro-angiogenic factors including VEGF (62, 63), we hypothesized that SRGN may facilitate angiogenesis by augmenting VEGF signaling in the TME.”
InfluentialLi, B., Yan, C., Zhu, J., Chen, X., Fu, Q., Zhang, H., Tong, Z., Liu, L., Zheng, Y., Zhao, P., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01037 · Cited by 132
Turning Tumors into Vaccines: Co-opting the Innate Immune System
van den Boorn, J. G., & Hartmann, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.011 · Cited by 116 · cited 1×
“The PD-1 signaling and CTLA4 pathway are well-known immune checkpoint pathways that tumors often exploit to evade immune surveillance (57 – 60).”
Chen, F., Lei, L., Chen, S., Zhao, Z., Huang, Y., Jiang, G., Guo, X., Li, Z., Zheng, Z., & Wang, J. (2022) · Nature Communications · doi:10.1038/s41467-023-44313-9 · Cited by 109 · cited 1×
“In addition, macrophages may be recruited through SRGN, as shown in myeloma (70) and disc degeneration (71).”
Self-citationAnnotation of cell types (ACT): a convenient web server for cell type annotation
Quan, F., Liang, X., Cheng, M., Yang, H., Liu, K., He, S., Sun, S., Deng, M., He, Y., Liu, W., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01249-5 · Cited by 105 · cited 1×
“Cell type annotation was achieved by manual mapping against liver-speci fi c marker genes obtained from the ACT database (http:// xteam.xbio.top/ACT/index.jsp) ( 29, 30), and supplemented by automated scoring via the UCell algorithm based on cell-type signature gene sets (31).”
Neutrophil elastase depends on serglycin proteoglycan for localization in granules
Niemann, C. U., Åbrink, M., Pejler, G., Fischer, R. L., Christensen, E. I., Knight, S. D., & Borregaard, N. (2007) · Blood · doi:10.1182/blood-2006-02-001719 · Cited by 100
CROST: a comprehensive repository of spatial transcriptomics
Wang, G., Wu, S., Xiong, Z., Qu, H., Fang, X., & Bào, Y. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad782 · Cited by 96
Chondroitin sulfate proteoglycans as novel drivers of leucocyte infiltration in multiple sclerosis
Stephenson, E. L., Mishra, M. K., Moussienko, D., Laflamme, N., Rivest, S., Ling, C.-C., & Yong, V. W. (2018) · Brain · doi:10.1093/brain/awy033 · Cited by 85 · cited 2×
“…, SRGN overexpression conferred proliferative advantage in vitro and tumorigenic capacity in vivo , directly establishing its pro-tumorigenic function in PLC. SRGN expression can be induced during the differentiation of monocytes into macrophages or upon macrophage activation (8, 11).”
Tanaka, I., Daydé, D., Tai, M.-C., Mori, H., Solis, L. M., Tripathi, S. C., Fahrmann, J. F., Ünver, N., Parhy, G., Jain, R., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab183 · Cited by 83 · cited 2×
“Similar discrepancy occurred between the present study about other cancers and several published reports (20, 21, 48, 49).”
Lee, J. Y., Kang, S. R., & Yune, T. Y. (2015) · Journal of Neurotrauma · doi:10.1089/neu.2014.3527 · Cited by 71
Ayala, T. S., Tessaro, F. H. G., Jannuzzi, G. P., Bella, L. M., Ferreira, K. S., & Martins, J. O. (2019) · Scientific Reports · doi:10.1038/s41598-019-47836-8 · Cited by 68
Modulation of the Expression of Chondroitin Sulfate Proteoglycan in Stimulated Human Monocytes
Uhlin‐Hansen, L., ESKELAND, T., & Kolset, S. O. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)63789-5 · Cited by 67
Guo, J.-Y., Chiu, C.-H., Wang, M.-J. S., Li, F., & Chen, J.-Y. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0600-3 · Cited by 62 · cited 1×
“Despite the properties of SRGN in both immunity and malignancy (10, 18, 24 – 26), its speci fi c role within the TME remains incompletely studied through a paracrine signaling pathway.”
Chu, Q. Q., Huang, H., Huang, T., Cao, L., Peng, L., Shi, S., Zheng, L., Xu, L., Zhang, S., Huang, J.-L., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.287 · Cited by 59
Manou, D., Karamanos, N. K., & Theocharis, A. D. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.004 · Cited by 59
Bo, N., Yilin, H., Chaoyue, Y., Lu, L., & Yuan, Y. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111679 · Cited by 56
SRGN, a new identified shear-stress-responsive gene in endothelial cells
Ma, Q., Gu, W., Li, T., Zhang, K., Cui, Y., Qu, K., Wang, N., Humphry, R., Durkan, C., Qiu, J., et al. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03830-7 · Cited by 52 · cited 4×
“The Matrigel (BD Company, 356234, USA) was added 150-200uL to each well of 48-well plates, and solidi fi ed at 37°°C for more than 2h. Human umbilical vein endothelial cells (HUVECs) were incubated with serum-free medium of respective HepG2SG and HepG2-NC for 12 h, then added 2×10 4 cells/200uL medium to each well, the…”
InfluentialSerglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients
He, L., Zhou, X., Qu, C., Tang, Y., Zhang, Q., & Hong, J. (2013) · Medical Oncology · doi:10.1007/s12032-013-0707-4 · Cited by 50 · cited 6×
“It has been studied in various immune cells — including neutrophils, macrophages, CD8+ T cells, etc., where it helps maintain immune cell population homeostasis by controlling the magnitude and durability of immune responses (10 – 15).”
InfluentialSutton, V. R., Brennan, A. J., Ellis, S. L., Danne, J., Thia, K. Y. T., Jenkins, M. R., Voskoboinik, I., Pejler, G., Johnstone, R. W., Andrews, D. M., et al. (2016) · FEBS Journal · doi:10.1111/febs.13649 · Cited by 48 · cited 1×
“…described above, SRGN levels were highest in M2 macrophages than other three monocyte/macrophage subsets in liver tissues, LIHC, and adjacent normal by GEPIA, re fl ecting the liver ’ s natural immune tolerance, immunosuppressive properties and pro-tumorigenic characteristics, respectively (66, 67).”
Yang, T., Fu, Z., Zhang, Y., Wang, M., Mao, C., & Ge, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110465 · Cited by 46
Increased Expression of Serglycin in Specific Carcinomas and Aggressive Cancer Cell Lines
Korpetinou, A., Papachristou, D. J., Lampropoulou, A., Bouris, P., Labropoulou, V., Noulas, A., Karamanos, N. K., & Theocharis, A. D. (2015) · BioMed Research International · doi:10.1155/2015/690721 · Cited by 42
Zhu, Y. K., Lam, A. K.-Y., Shum, D. K., Cui, D., Zhang, J., Yan, D., Li, B., Xu, W., Lee, N. P. Y., Chan, K. T., et al. (2021) · Theranostics · doi:10.7150/thno.49547 · Cited by 33
Self-citationRadiofrequency ablation of hepatocellular carcinoma: Current status, challenges, and prospects
Wang, H., Wu, Z., Cui, D., Shi, Y., & Zhai, B. (2023) · Liver Research · doi:10.1016/j.livres.2023.05.002 · Cited by 32 · cited 1×
“Hepatocellular carcinoma (HCC), accounting for approximately 90% of primary liver cancer (PLC), represents the fourth leading cause of cancer-related mortality globally (1, 2).”
Johnson, R. P., Ratnacaram, C. K., Kumar, L., & Jose, J. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100865 · Cited by 27
Grujić, M., Christensen, J. P., Sørensen, M. R., Åbrink, M., Pejler, G., & Thomsen, A. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.1043 · Cited by 27
Wang, X., Xiong, H., Liang, D., Chen, Z., Li, X., & Zhang, K. (2020) · BMC Cancer · doi:10.1186/s12885-020-06849-7 · Cited by 25
Self-citationZahran, A. M., Abdel-Rahim, M. H., Refaat, A., Sayed, M. M., Othman, M. M., Khalaf, L. M. R., & Hetta, . F. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1657940 · Cited by 25
Platelet α‐granule cargo packaging and release are affected by the luminal proteoglycan, serglycin
Chanzu, H. A., Lykins, J. T., Wigna‐Kumar, S., Joshi, S., Pokrovskaya, I. D., Storrie, B., Pejler, G., Wood, J. P., & Whiteheart, S. W. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15243 · Cited by 25
Manou, D., Bouris, P., Kletsas, D., Götte, M., Greve, B., Moustakas, A., Karamanos, N. K., & Theocharis, A. D. (2020) · Matrix Biology Plus · doi:10.1016/j.mbplus.2020.100033 · Cited by 25
Tellez-Gabriel, M., Tekpli, X., Reine, T. M., Hegge, B., Nielsen, S. R., Chen, M., Moi, L. L. H., Normann, L. S., Busund, L., Călin, G. A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.868868 · Cited by 24
Ali, M. H. M., Toor, S. M., Rakib, F., Mall, R., Ullah, E., Mroué, K. H., Kolatkar, P. R., Al‐Saad, K. A., & Elkord, E. (2019) · Vaccines · doi:10.3390/vaccines7030109 · Cited by 22
Wang, J., Chen, X., Wu, D., Jia, C., Lian, Q., Pan, Y., & Yang, J. (2024) · Liver Research · doi:10.1016/j.livres.2024.11.001 · Cited by 18
Self-citationYu, Y., Tang, H., Franceschi, D., Mujagond, P., Acharya, A., Deng, Y., Lethaus, B., Savković, V., Zimmerer, R. M., Ziebolz, D., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.759605 · Cited by 18
Li, L., Xu, L., Lian, Q., Wang, X., Jia, C., & Xu, C. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04546-5 · Cited by 17
Self-citationQuality of life in patients with HBV infection: A systematic review and meta-analysis
Fu, M. X., Lambert, G., Cook, A., Ndow, G., Haddadin, Y., Shimakawa, Y., Hallett, T. B., Harvala, H., Sicuri, E., Lemoine, M., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2024.101312 · Cited by 17 · cited 1×
“A key etiological factor is hepatitis B virus (HBV) infection, which alone affects an estimated 250 million individuals worldwide (4, 5).”
Yang, F., Ni, B., Lian, Q., Qiu, X., He, Y., Zhang, Q., Zou, X., He, F., & Chen, W. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1066410 · Cited by 17 · cited 1×
“Gene Set Enrichment Analysis (GSEA) was performed using the clusterPro fi ler package to further explore the biological functions and pathways associated with the DEGs (32, 33).”
Self-citationLiu, Q., Lian, Q., Song, Y., Yang, S., Jia, C., & Fang, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1119945 · Cited by 17
Self-citationJi, F., Zhang, J., Mao, L., Tan, Y., Ye, M., He, X., Zhao, Y., Liu, J., Zhang, Y., Zhang, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55745-2 · Cited by 16
Self-citationBidirectional Tumor-Promoting Activities of Macrophage Ezrin
Khan, K., Long, B., Deshpande, G. M., & Fox, P. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207716 · Cited by 16
Wang, Y., Ren, D., Lu, J., Jiang, H., Wei, J., Lan, J. X., Liu, F., & Qu, S. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00733-7 · Cited by 14 · cited 1×
“In glioblastoma, STAT3 phosphorylation was suppressed through SRGN knockdown (19); in contrast, STAT3 induced SRGN in nasopharyngeal carcinoma (69), suggesting a potential positive feedback loop in tumor cells that may also operate in TAMs, thereby sustaining a potent oncogenic signaling circuit.”
Yang, F., Lian, Q., Ni, B., Qiu, X., He, Y., Zou, X., He, F., & Chen, W. (2022) · Liver Research · doi:10.1016/j.livres.2022.12.002 · Cited by 14
Self-citationChen, F., Li, Q., Xu, X., & Wang, F. (2023) · Liver Research · doi:10.1016/j.livres.2023.07.004 · Cited by 14 · cited 1×
“A key etiological factor is hepatitis B virus (HBV) infection, which alone affects an estimated 250 million individuals worldwide (4, 5).”
Zhang, Y., Liang, X., Lian, Q., Liu, L., Zhang, B., Dong, Z., & Liu, K. (2023) · BMC Cancer · doi:10.1186/s12885-023-10987-z · Cited by 13
Self-citationHuo, X., Jiang, S., Wu, S., Lian, Q., & Chen, H. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.002 · Cited by 12
Self-citationZhang, S., Hu, H., Li, X., Chen, Q., Zheng, Y., Peng, H., Mo, Z., Hu, W., Li, Y., Hong, S., et al. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.108151 · Cited by 11
Self-citationYin Yang Gong Ji pill is an ancient formula with antitumor activity against hepatoma cells
Li, Y., Li, Y., Zou, Z., Li, Y., Xie, H., & Yang, H. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112267 · Cited by 11
Self-citationSRGN promotes macrophage recruitment through CCL3 in osteoarthritis
Zhang, Y., Li, Z., Chen, C., Wang, W. T., Li, Z., Zhou, H., He, W., Jiang, X., Li, B., & Yang, Y. (2024) · Connective Tissue Research · doi:10.1080/03008207.2024.2380313 · Cited by 8
Yan, D., Cui, D., Zhu, Y., Chan, C. K. W., Choi, C. H. J., Liu, T., Tsao, S. W., Ma, S., & Cheung, A. L. M. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1031 · Cited by 6
Li, Y., Chen, H., Lu, H., Zou, Z., & Li, Y. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666201020112459 · Cited by 3
Self-citationHuang, M., Chen, X., Yi, J., & Chan, L. (2025) · Bioengineering · doi:10.3390/bioengineering12030322 · Cited by 3
Research works printed but not linked: 1
- Li, 2013, Expression of serglycin in HepG2 cells with different HBV infection status
Cited by
Wu, D., Liu, C., Zhan, L., Liang, M., Li, Q., & Lian, Q. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102853 · Cited by 7
“To assign cell identities, we cross ‑ referenced cluster ‑ specific marker genes against known cell ‑ type signatures documented in the original publication [2], ACT database [20 – 23], DeepCellSeek (https://deepcellseek.kiz.ac.cn/) and the Cell-Marker 2.0 repository.”
InfluentialSelf-citationLiu, J., Chen, X., Liu, C., Yang, C., & Li, B. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102722 · Cited by 3
“Through systematic assessment, a clustering resolution of 0.1 was identified as optimal for subsequent visualization and analysis [33].”
InfluentialZhang, M., Zhao, Z., Zhu, Q., Liang, S., Sun, L., Wei, H., Liu, S. S., Zhao, M., Li, L., & Wang, L. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102927 · Cited by 2
Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review
Chen, S., Tu, L., & Chen, Q. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1898418 · Cited by 1
“Lian et al. (Lian et al., 2025) identified the proteoglycan Serglycin as a critical extracellular modulator in primary liver cancer, demonstrating that it shapes an immunosuppressive tumor microenvironment by orchestrating interactions with tumor-associated macrophages.”
AJUBA: The Master Regulator Bridging EMT and Immune Evasion in Colorectal Cancer
Shen, W., Cui, M., Liao, X., Xiong, Y., Zou, B., Zhang, X., & Shao, C. (2026) · Mediators of Inflammation · doi:10.1155/mi/7828477 · Cited by 1
“GAPDH (1:5,000; Proteintech Group, Inc.) served as the internal loading control [31].”
Metadata
- Authors
- Lian, Q., Ma, C., Wang, X., Wang, J., Zeng, J., Zhang, J., & Li, Y.
- Affiliations
- Sun Yat-sen University (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Corresponding author
- Zeng, Jindi
- Zhang, Jiongshan
- Li, Yongwei
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2025-12-16
- Volume
- 16
- Pages
- 1668627-1668627
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC12748857
- OpenAlex
- W4417356273
- Cited by
- 10
- References
- 67
- Citations by year
- 2026: 10
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Universidade de Macau
- Basic and Applied Basic Research Foundation of Guangdong Province
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- serglycin, primary liver cancer, hepatocellular carcinoma, tumor microenvironment, tumor-associated macrophages, TAM polarization, M2 macrophages, NF-κB signaling, STAT3 signaling, sorafenib resistance, angiogenesis, VEGF signaling, proteoglycans, prognostic factors
- MeSH terms
- Tumor-Associated Macrophages, Animals, Cell Communication, Cell Movement, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Macrophages, Male, Mice, Nude, Proteoglycans, Signal Transduction, Vesicular Transport Proteins, Cell Line, Tumor, Cell Proliferation, Mice, Hep G2 Cells, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.